Posted by Michael Wonder on 17 Aug 2021
Agios announces FDA acceptance and priority review of new drug application for mitapivat for treatment of adults with pyruvate kinase deficiency
17 August 2021 - PDUFA date set for 17 February 2022.
Agios Pharmaceuticals today announced that the U.S. FDA has accepted the company’s new drug application for mitapivat for the treatment of adults with pyruvate kinase deficiency.
